Act Capital Management, LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Act Capital Management, LLC reported 58 stock positions worth $123.7 million. Its top holding was Krystal Biotech (KRYS) at 12.1% of the portfolio, followed by Chevron (CVX, 9.7%) and Exxon Mobil (XOM, 8.0%).
- Most Recent 13F
- Q2 2026
- Location
- WAYNE, PA
- CIK
- 0001442273
- Portfolio Value
- $123.7M (Q4 2025)
- SEC Filing
- 0001636587-26-000006 ↗ filed Feb 17, 2026
Holdings Value
Holdings 58 stocks · $123.7M
| KRYS Krystal Biotech Inc. | 12.06% | 60,500 | $14.9M | — |
| CVX Chevron Corp. | 9.67% | 78,500 | $12.0M | — |
| XOM Exxon Mobil Corp. | 8.03% | 82,500 | $9.9M | — |
| ABVX Abivax SA-ADR | 6.97% | 63,900 | $8.6M | — |
| TGTX TG Therapeutics Inc. | 6.48% | 268,875 | $8.0M | — |
| VKTX Viking Therapeutics Inc. | 5.86% | 206,100 | $7.3M | — |
| CELC Celcuity Inc. | 5.11% | 63,415 | $6.3M | — |
| AMZN Amazon.com Inc. | 4.59% | 24,600 | $5.7M | — |
| NUVB Nuvation Bio Inc. | 4.42% | 610,500 | $5.5M | — |
| ARWR Arrowhead Pharmaceuticals Inc. | 4.03% | 75,000 | $5.0M | — |
| CYTK Cytokinetics Inc. | 3.31% | 64,500 | $4.1M | — |
| CELCUITY INC COM MAR 20 26 $50 CALL (CELC) | 2.46% | 30,500 | $3.0M | — |
| GPCR Structure Therapeutics Inc. | 2.17% | 38,500 | $2.7M | — |
| GBTC Grayscale Bitcoin Trust ETF | 1.90% | 34,400 | $2.4M | — |
| FIGR Figure Technology Solut Class A | 1.90% | 57,500 | $2.3M | — |
| SPOT Spotify Technology SA | 1.88% | 4,000 | $2.3M | — |
| ET Energy Transfer LP | 1.77% | 133,100 | $2.2M | — |
| NKTR Nektar Therapeutics | 1.75% | 51,200 | $2.2M | — |
| OLMA Olema Pharmaceuticals Inc. | 1.08% | 53,500 | $1.3M | — |
| IBM Intl Business Machines Corp. filed as INTERNATIONAL BUSINESS MACHS | 1.08% | 4,500 | $1.3M | — |
| STAA Staar Surgical Co. | 1.04% | 55,500 | $1.3M | — |
| CELCUITY INC COM MAR 20 26 $35 CALL (CELC) | 1.01% | 12,500 | $1.2M | — |
| RGNX Regenxbio Inc. | 0.96% | 82,500 | $1.2M | — |
| BE Bloom Energy Corp. Class A | 0.91% | 13,000 | $1.1M | — |
| HCC Warrior Met Coal Inc. | 0.86% | 12,000 | $1.1M | — |
| EOG EOG Resources Inc. | 0.85% | 10,000 | $1.1M | — |
| SNDK Sandisk Corp. | 0.67% | 3,500 | $831K | — |
| DVN Devon Energy Corp. | 0.65% | 22,000 | $806K | — |
| PATH Uipath Inc. Class A | 0.62% | 47,000 | $770K | — |
| KURA Kura Oncology Inc. | 0.62% | 73,900 | $768K | — |
| TEVA Teva Pharmaceutical-SP ADR | 0.58% | 23,000 | $718K | — |
| REPL Replimune Group Inc. | 0.48% | 61,500 | $598K | — |
| SRRK Scholar Rock Holding Corp. | 0.43% | 12,000 | $529K | — |
| APGE Apogee Therapeutics Inc. | 0.43% | 7,000 | $528K | — |
| CRGY Crescent Energy Inc. Class A | 0.42% | 61,312 | $514K | — |
| WGS Genedx Holdings Corp. | 0.32% | 3,000 | $390K | — |
| PALI Palisade Bio Inc. | 0.28% | 150,000 | $353K | — |
| ACOG Alpha Cognition Inc. | 0.27% | 51,500 | $335K | — |
| LQDA Liquidia Corp. | 0.24% | 8,500 | $293K | — |
| KYTX Kyverna Therapeutics Inc. | 0.19% | 25,100 | $236K | — |
| BW Babcock & Wilcox Enterpr | 0.19% | 36,500 | $231K | — |
| ALDX Aldeyra Therapeutics Inc. | 0.17% | 41,000 | $212K | — |
| NKLR Terra Innovatum Global NV | 0.17% | 45,000 | $208K | — |
| PRAX Praxis Precision Medicines I | 0.17% | 700 | $206K | — |
| ESPR Esperion Therapeutics Inc. | 0.14% | 47,500 | $176K | — |
| LSPD Lightspeed Commerce Inc. | 0.12% | 12,500 | $151K | — |
| DAWN Day One Biopharmaceuticals I | 0.10% | 12,900 | $120K | — |
| TVTX Travere Therapeutics Inc. | 0.09% | 3,000 | $115K | — |
| AMLX Amylyx Pharmaceuticals Inc. | 0.09% | 9,000 | $109K | — |
| WY Weyerhaeuser Co. | 0.09% | 4,500 | $107K | — |
| SSYS Stratasys Ltd. | 0.07% | 10,000 | $87K | — |
| BHVN Biohaven Ltd. | 0.07% | 7,500 | $85K | — |
| BTC Grayscale Bitcoin Mini ETF | 0.06% | 1,800 | $70K | — |
| CAPR Capricor Therapeutics Inc. | 0.04% | 1,500 | $43K | — |
| NVNO Envveno Medical Corporation | 0.03% | 115,000 | $37K | — |
| YALA Yalla Group Ltd. | 0.03% | 5,000 | $35K | — |
| PDSB PDS Biotechnology Corp. | 0.02% | 30,000 | $23K | — |
| MLTX Moonlake Immunotherapeutics | 0.02% | 1,500 | $20K | — |
Portfolio Sells Q4 2025
No earlier filing to compare with.
Portfolio Buys Q4 2025
No earlier filing to compare with.